Qlinebiotech earnings calls.

Qline Biotech delivered a landmark FY26 with revenue of Rs 341.7 croreCurrent reported value: revenue of Rs 341.7 crore. No comparable prior figure is available in the source record. (9Current reported value: 9. No comparable prior figure is available in the source record.% YoY) but margin expansion was the standout story — EBITDA surged 39% to Rs 98.1 croreCurrent reported value: 39% to Rs 98.1 crore. No comparable prior figure is available in the source record. with margins jumping 620bps to 28.7%Current reported value: 620bps to 28.7%. No comparable prior figure is available in the source record., driven by manufactured reagents now comprising ~70% of revenue with 60-65% margins. PAT nearly tripled to Rs 55.7Current reported value: 55.7. No comparable prior figure is available in the source record. crore though FY25 base was depressed by prior-period expenses. The installed base of 1,550 Selectra Pro analyzersCurrent installed base of 1,550 Selectra Pro analyzers. Reported change: +450 units YoY. creates durable recurring revenue (Rs 3 lakh per instrument over 10-year life), while Unit 4 at Baddi provides 3-4x capacity headroomCurrent reported value: 3-4x capacity headroom. No comparable prior figure is available in the source record.. Management guided to 30-35% revenue growth for FY27Current reported value: 30-35% revenue growth for FY27. No comparable prior figure is available in the source record. while maintaining profitability focus, with exports targeted at 5x (Rs 1.2 crore to Rs 6 crore) and CDMO contributions of Rs 10 crore. The key risks remain geographic concentration (77% from UP via a related-party distributor), B2G dependence (65%), and technology/licensing dependencies on instrument partnerships. Near-term catalysts include Unit 4 utilization ramp (targeting 25-30% in FY27), new product launches (Microlab 300), and export market expansion.